NASDAQ: VERAVera Therapeutics Inc Stock
$7.48+0.35 (+4.91%)
Updated Mar 20, 2023
VERA Price
$7.48
Fair Value Price
N/A
Market Cap
$206.88M
52 Week Low
$5.20
52 Week High
$24.94
P/E
-2.38x
P/B
1.96x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$53M
Beta
0.96
Next Earnings
Mar 23, 2023
Ex-Dividend
N/A
Next Dividend
N/A
VERA Overview
Vera Therapeutics, Incorporated develops treatments for patients with serious immunological diseases in the U.S. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. Known as Trucode Gene Repair, Inc. until 2020, Vera Therapeutics was incorporated in 2016 and is headquartered in Brisbane, CA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VERA is good value based on its book value relative to its share price (1.96x), compared to the US Biotechnology industry average (4.81x)
P/B vs Industry Valuation
VERA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VERA due diligence checks available for Premium users.
Be the first to know about important VERA news, forecast changes, insider trades & much more!
VERA News
Valuation
VERA fair value
Fair Value of VERA stock based on Discounted Cash Flow (DCF)
Price
$7.48
Fair Value
$10.26
Undervalued by
27.09%
VERA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.38x
Industry
16.1x
Market
22.37x
VERA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.96x
Industry
4.81x
VERA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERA's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.7M
Profit Margin
0%
VERA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$131.4M
Liabilities
$25.7M
Debt to equity
0.24
VERA's short-term assets ($124.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERA's short-term assets ($124.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.4M
Investing
-$2.4M
Financing
$908.0k
VERA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERA vs Biotech Stocks
Vera Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.